TRIPS and Access to Medicines: Patents and Public Health

Intellectual property defines who may economically exploit protected creations and technical information. In the case of medicines, that legal control bears on an immediate material need: a pharmaceutical discovery improves a person’s life only when the product reaches a health service or a pharmacy on terms compatible with treatment. This places pharmaceutical patents beyond business policy. They connect innovation, international trade, public budgets, and the right to health.

The Agreement on Trade-Related Aspects of Intellectual Property Rights, known by the English acronym TRIPS, brought that tension inside the World Trade Organization (WTO). Since 1995, WTO members have had to comply with minimum standards of intellectual property protection, including patent protection. At the same time, the agreement itself preserves tools that allow governments to pursue public objectives, including the protection of health. In practice, access to medicines depends on patent review, public procurement policy, and the ability to authorize alternative production or importation under health regulation. Sufficient protection can encourage research and technology transfer, while poorly managed exclusivity can delay the entry of generics, raise prices, and reduce the response capacity of health systems.

Summary

• TRIPS turned intellectual property into a matter of multilateral trade discipline and gave pharmaceutical patents a common basis within the WTO.
• Patents can encourage research by granting temporary exclusivity and raise prices when there is no generic competition, strong public procurement, or alternative production.
• The agreement’s flexibilities, such as compulsory licenses and government use, allow exclusivity to be limited in situations of public interest without eliminating the patent.
• The 2001 Doha Declaration strengthened the interpretation that TRIPS must be applied in a way compatible with the right of WTO members to protect public health.
• Article 31bis addressed the problem of countries without sufficient pharmaceutical capacity by allowing exports of medicines produced under compulsory license in certain conditions.
• The COVID-19 pandemic showed that intellectual property is one part of access: vaccines, diagnostics, and therapeutics depend as well on technology transfer, inputs, factories, health regulation, and public procurement.

How TRIPS Brought Patents Into the WTO

Before the WTO, intellectual property was already addressed by international conventions administered largely by the World Intellectual Property Organization (WIPO). Those conventions organized principles, cooperation, and recognition of rights without the same system of trade dispute settlement that would later exist in the WTO. TRIPS changed this architecture by tying intellectual property to the legal package of the Uruguay Round, concluded in 1994, and placing certain intellectual property obligations inside a trade regime with stronger diplomatic consequences.

The agreement covers more than patents. It brings together different forms of protection over creation, commercial identification, industrial design, and confidential business information. In addition to those substantive fields, it establishes rules on domestic implementation, measures against infringement, and transparency procedures. That breadth explains why TRIPS became a central reference for trade in knowledge, technology, and intangible goods.

In the field of patents, the agreement requires members to make protection available for inventions that are new, involve an inventive step, and are capable of industrial application. The rule applies to products and processes in all fields of technology, with limited exceptions, and protection must not end before twenty years counted from the filing date of the application. In practical terms, many countries had to adapt their laws to recognize pharmaceutical patents more broadly than before, which changed the margin for action available to purchasing governments and generic producers.

That change affected countries at different stages of industrial development. Economies with strong pharmaceutical companies gained more predictable protection to sell, license, and defend their products abroad. Countries dependent on imports or with a developing generic industry, by contrast, faced higher costs to absorb protected technology. The rule shifted power among right holders, purchasing governments, and generic producers. Populations that depend on essential medicines feel that shift when price, public procurement, and alternative production determine whether treatment continues.

Why Patents Change the Price of Medicines

A patent grants the holder a temporary exclusive right over the invention. In the pharmaceutical sector, that right may protect the active substance, the dosage form, or a technical method of manufacture. The concrete scope depends on national law and on the agreement’s requirements. During the protection period, third parties need authorization to commercially exploit the patented product, unless a legal exception allows otherwise.

The argument in favor of patents is straightforward. Developing medicines can require years of research, regulatory approval, and risk of failure before production at scale. Temporary exclusivity promises to turn scientific risk into a predictable economic return. It allows companies to recover part of those costs, attracts private capital, and encourages technical disclosure of the invention. Without some degree of protection, certain products could be copied before the investor recovered the research expense.

The effect on access, however, depends on market structure. When a patented medicine has no adequate therapeutic substitute, the holder can negotiate from a very strong position. Governments can buy at large scale and try to reduce prices. Their budget, negotiating strength, and regulatory capacity vary sharply. Families that pay directly for treatment face even greater pressure, as the medicine’s price becomes a barrier to obtaining care.

Generics change this relationship by introducing competition under health regulation. When several companies can produce an equivalent medicine approved by a health authority, the price tends to fall, and public programs can treat more people with the same budget. The tension appears when the need for treatment arrives before exclusivity ends. In those cases, the discussion moves from private property to the state’s capacity to protect public health.

Public Health Flexibilities in TRIPS

TRIPS leaves room for public policy. The agreement links intellectual property protection to innovation, technology dissemination, and a balance of rights and obligations. Its principles recognize that members may adopt measures necessary to protect public health and nutrition, as long as those measures are compatible with the agreement.

In practice, the flexibilities appear through different pathways. A government may define rigorous patentability criteria to avoid protection for trivial changes that do not meet the threshold for an invention. It may provide limited exceptions to patent rights, such as regulatory uses needed to prepare the entry of generics after protection ends. It may use competition rules to address abusive practices or authorize the use of a patent without the holder’s consent, under the conditions set out in Article 31.

That authorization without consent is usually called a compulsory license, although the agreement uses the broader phrase “other use without authorization of the right holder.” A compulsory license leaves the patent in force. It allows the government, or a company authorized by it, to use the invention for a defined purpose, and the holder remains entitled to adequate remuneration. The license limits exclusivity in a specific case without extinguishing the patent right. The phrase “breaking a patent” is imprecise.

Authorization without consent must have a defined purpose, be subject to possible review, and provide adequate remuneration. It must be assessed on its own merits and, as a rule, come after a prior attempt to obtain a voluntary license on reasonable commercial terms. That attempt may be waived in a national emergency, in circumstances of extreme urgency, or for public non-commercial use. This structure seeks to make room for public health without turning compulsory licensing into routine confiscation.

Doha and the Antiretroviral Crisis

The tension between TRIPS and public health became central in the late 1990s and early 2000s. Antiretroviral medicines already existed, yet many poor countries faced unaffordable prices. The HIV/AIDS epidemic exposed the distance between the scientific existence of a treatment and the real capacity to distribute it. Governments, humanitarian organizations, patient movements, and generic producers began to press for intellectual property rules that would leave room for national responses to the crisis.

Brazil, India, and South Africa converted national experiences with access into multilateral pressure. Brazil tied AIDS treatment to Brazil’s Unified Health System (Sistema Único de Saúde, SUS) and used the possibility of compulsory licensing as a tool for price negotiation. India had a generic industry capable of producing medicines at lower costs. South Africa faced a deep health crisis and an intense political dispute over access to antiretrovirals. Those countries’ coordination turned a health problem into a diplomatic conflict inside the WTO.

In 2001, the WTO Ministerial Conference adopted the Doha Declaration on the TRIPS Agreement and Public Health. The text stated that the agreement should be interpreted in a way favorable to members’ right to protect public health and promote access to medicines for all. The declaration recognized that each member has the right to grant compulsory licenses and to determine the grounds upon which such licenses are granted. By mentioning epidemics such as HIV/AIDS, tuberculosis, and malaria, the declaration reinforced the interpretation that health crises may represent a national emergency or a circumstance of extreme urgency.

The strength of the Doha Declaration was interpretive and political. It reduced uncertainty about the legitimacy of public health measures under TRIPS and strengthened countries that needed to negotiate prices, produce generics, or organize procurement in a crisis. TRIPS remained in force, with public health guiding its interpretation more clearly.

The Problem of Countries Without Pharmaceutical Production

The Doha Declaration made a practical flaw clear. Compulsory licensing worked better for countries able to manufacture the medicine domestically. Article 31(f) provided that authorized use should supply predominantly the domestic market of the member that granted the license. That rule made it difficult to export, at large scale, generics produced under compulsory license to countries without sufficient pharmaceutical industry.

The problem was concrete. A country without factories, inputs, technical staff, or production scale would not be able to turn a compulsory license into pills available to its population. If another country with manufacturing capacity were prevented from exporting the medicine in sufficient volume, the flexibility would exist only on paper. Without manufacturing capacity, compulsory licensing becomes legal authorization without available treatment. Paragraph 6 of the Doha Declaration recognized that difficulty and instructed the TRIPS Council to find a solution.

In 2003, WTO members approved a temporary decision that removed the obstacle of Article 31(f) under certain conditions. The system allowed an exporting country to grant a compulsory license to produce a medicine destined for an importing country with insufficient or nonexistent capacity in the pharmaceutical sector. The arrangement required notifications, identification of the product, the necessary quantity, and safeguards against commercial diversion.

In 2005, members decided to turn that mechanism into a permanent amendment to TRIPS. The amendment, known as Article 31bis, entered into force in 2017, when it reached the required number of acceptances. Its objective is to provide a stable legal basis for exporting generic medicines produced under compulsory license to members without adequate manufacturing capacity. Even so, its use is limited by complex procedures and by the need for compatible domestic legislation. Practical application requires coordination among the purchasing government, the authorized producer, the health authority, and the patent holder.

Voluntary Licenses, Public Procurement, and Manufacturing Capacity

Compulsory licensing is the most visible instrument among several paths to expand access. In many situations, governments and international organizations try to obtain voluntary licenses, in which the holder authorizes other manufacturers to produce or sell the medicine in certain countries. The advantage is to reduce legal conflict and accelerate production when the parties cooperate. The limit appears when the license authorizes production without removing significant commercial or technical barriers. Under those conditions, formal authorization yields limited affordable supply.

The Medicines Patent Pool emerged precisely to organize part of this terrain. The mechanism negotiates public-interest licenses with patent holders and sublicenses generic manufacturers in areas such as HIV, tuberculosis, and hepatitis C. In recent years, it has begun to cover treatments linked to COVID-19. Public-interest licenses can turn exclusivity into competitive production when the territorial, technical, and commercial terms allow manufacturing for those who need it. The effectiveness of the model depends in turn on holders’ willingness to license.

Public procurement changes the balance. A government buying for a national health system can negotiate volume, provide for local production, stimulate competition, and plan inventories. When public policy is fragmented or when families buy individually, the monopoly price weighs more directly on access. The same patent can produce different effects depending on the purchaser’s institutional strength.

Manufacturing capacity is the other decisive element. A country may have a legal basis to use flexibilities and still depend on imports when it lacks the necessary industrial and regulatory infrastructure. The COVID-19 pandemic made this point clear: intellectual property was one part of the problem. Producing vaccines, tests, and therapeutics required supply chains, industrial plants able to receive technology, and tacit knowledge accumulated by manufacturing teams.

COVID-19 and the Dispute Over Patent Waivers

In 2020, India and South Africa proposed at the WTO a temporary waiver of certain intellectual property obligations related to COVID-19. The proposal responded to the fear that products against the pandemic would remain concentrated in rich countries, while low- and middle-income countries would wait for real access to the technology. The debate opposed emergency legal access to the claim that production barriers lay mainly outside patent law. Supporters of the waiver invoked the global scale of the crisis. Governments and pharmaceutical companies feared a loss of incentives and weaker private cooperation.

The 2022 outcome was more restricted than the original proposal. At the WTO’s 12th Ministerial Conference, members adopted a TRIPS decision aimed at the production and supply of COVID-19 vaccines. The 2022 decision covered vaccines and remained narrower than the broad waiver requested at the beginning of the pandemic. It allowed eligible developing members to authorize the use of patented subject matter necessary for production without the holder’s consent, waive the requirement of a prior attempt to obtain authorization, and export any proportion of the products manufactured under that authorization to other eligible members. The text preserved the idea of adequate remuneration and established a five-year term.

At that moment, diagnostics and therapeutics were left outside the decision. Members were supposed to decide later whether to extend the regime to those products. Prolonged discussions produced no consensus. The impasse kept diagnostics and therapeutics outside the special regime and exposed the structural divide between countries with major pharmaceutical capacity and countries that depend on imports, licensing, or donations.

The COVID-19 debate added an important qualification to how patents are understood. In some technologies, the absence of a license can block manufacturing. In others, the central barrier lies in turning protected knowledge into safe production. That requires inputs, equipment, regulatory data, and capacity to scale, as well as trade secrets that patents do not always transfer. Patents organize protected technical knowledge. Practical industrial capacity depends on inputs, skills, and institutions beyond the patent itself. Access to medicines accordingly requires health regulation, financing, public procurement, logistics, technology transfer, and public trust.

Innovation and Public Health

The dispute over TRIPS links corporate incentives, patient needs, and public funding. Pharmaceutical research requires incentives, and part of innovation depends on private investment. Many medical advances build on research financed by universities, governments, foundations, and future public procurement. When the state funds research, guarantees a market, or assumes procurement risk, private exclusivity must reflect that public contribution.

Defenders of strong protection argue that patents create predictability for high-risk investments. That predictability can favor the development of medicines, research partnerships, and clinical trials. Critics point to a poor match between the incentive and global health needs. Diseases that affect poor populations may remain underfunded. Products with greater commercial return, in turn, receive more attention. A patent rewards a paying market better than a health need without a strong buyer.

Access to medicines therefore requires complementary instruments. Public funds can steer research toward neglected diseases, and advance purchase commitments can create demand for priority vaccines or therapeutics. Open or socially conditioned licenses bring publicly funded innovation closer to generic production in low-income countries. Transparency rules help clarify the costs of research, development, and manufacturing. Competition measures can limit practices that artificially prolong exclusivities.

TRIPS sets the international floor, while national health policy determines implementation. Each government still needs to turn these rules into health policy. In legal terms, that requires reviewing patents and regulating prices. In health terms, it requires registering products, funding purchases, and maintaining supply capacity. The WTO provides rules and a dispute forum. The population receives or fails to receive the medicine according to how those rules are converted into concrete state capacity.

Public Health Systems and Access Diplomacy

TRIPS flexibilities matter most when they are connected to public health systems, procurement budgets and production or import capacity. Brazil is one classic example because HIV/AIDS treatment through the SUS gave the government a direct interest in reducing prices and guaranteeing supply. India’s generic industry and South Africa’s access struggle show the same broader point from different positions: legal flexibility becomes practical only when a government, producer or procurement system can turn it into affordable medicines.

This position does not require a general rejection of intellectual property. The conflict concerns the scope of exclusivity when it affects essential medicines. By defending the Doha Declaration and the possible use of compulsory licenses, access-oriented diplomacy treats public health as a legitimate foundation for trade policy.

The same experience reveals the limits of the instrument. Compulsory licensing can reduce prices in specific cases. Epidemiological surveillance, continuous funding, pharmaceutical assistance, domestic research and health regulation remain necessary. When the medicine requires complex technology or inputs concentrated among a few suppliers, the license solves only part of the chain. The tool changes negotiations by giving a government a credible legal alternative before the patent holder.

Legal and Industrial Limits of the Regime

The TRIPS–public health regime has three main limits. The first is procedural. Flexibilities may exist in the text, yet applying them requires national laws, legal teams, administrative authorities, and political willingness to face diplomatic and business pressure. Countries with low state capacity may hesitate even when the international rule allows them to act.

The second limit is productive. Modern medicines depend on industrial chains that involve active pharmaceutical ingredients, quality standards, specialized equipment, regulatory data, and certification. Where those elements are concentrated, legal authorization still needs productive capacity to become supply. Compulsory licensing needs to be accompanied by a capable producer, technical transfer, or an alternative supplier.

The third limit is distributive. TRIPS operates within an unequal world economy. Rich countries buy earlier, finance research, concentrate companies, and influence technical standards. Poor countries demand access from weaker positions, with smaller markets, fewer factories, and less diplomatic power. The Doha Declaration expanded those countries’ legal room for maneuver while the asymmetry that makes access unequal remained in place.

Those limits leave the flexibilities relevant as part of a broader policy. Intellectual property is one piece of that policy. When used well, flexibility allows governments to negotiate prices, respond to emergencies, and import generics. When isolated, it can become a legal victory without available treatment.

What Is at Stake in the Dispute

TRIPS placed pharmaceutical patents at the center of trade governance by turning intellectual property into a multilateral obligation with enforcement mechanisms. At the same time, the antiretroviral access crisis, the Doha Declaration, Article 31bis, and the COVID-19 debates showed that medicines occupy a dual position: they are commercial products and public health instruments.

The decisive question is how to turn medical knowledge into available treatment. Patents can help finance research and structure licensing. They can delay competition and raise prices when exclusivity weighs more than health systems’ capacity to pay. In the face of that tension, responses need to act at different stages of the same access chain. Compulsory licenses reduce the legal barrier when the public interest requires limiting exclusivity. Voluntary licenses can open authorized production before a harder conflict, as long as their terms allow service to those who need it. Public procurement gives demand scale and reduces uncertainty for suppliers. Local production and technology transfer, finally, turn authorization and purchasing into the capacity to manufacture or adapt treatments. Together, these instruments seek to keep innovation tied to access.

The dispute over TRIPS, patents, and medicines remains current. It asks who has a right over an invention and who can manufacture, buy, import, distribute, and receive the technology after it exists. At that point, intellectual property stops being only a technical topic for lawyers and becomes a question about the political structure of global health.